title: Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.
abstract: Understanding the origin and fate of organic impurities within the manufacturing process along with a good control strategy is an integral part of the quality control of drug substance. Following the underlying principles of quality by design (QbD), a systematic approach to analytical control of process impurities by impurity fate mapping (IFM) has been developed and applied to the investigation and control of impurities in the manufacturing process of Pazopanib hydrochloride, an anticancer drug approved recently by the U.S. FDA. This approach requires an aggressive chemical and analytical search for potential impurities in the starting materials, intermediates and drug substance, and experimental studies to track their fate through the manufacturing process in order to understand the process capability for rejecting such impurities. Comprehensive IFM can provide elements of control strategies for impurities. This paper highlights the critical roles that analytical sciences play in the IFM process and impurity control. The application of various analytical techniques (HPLC, LC-MS, NMR, etc.) and development of sensitive and selective methods for impurity detection, identification, separation and quantification are highlighted with illustrative examples. As an essential part of the entire control strategy for Pazopanib hydrochloride, analytical control of impurities with 'meaningful' specifications and the 'right' analytical methods is addressed. In particular, IFM provides scientific justification that can allow for control of process impurities up-stream at the starting materials or intermediates whenever possible.
authors.affiliation: Chemical Development, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, United States.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: David Q
authors.initials: DQ
authors.lastname: Liu
authors.forename: Shawn
authors.initials: S
authors.lastname: Yang
authors.forename: Ravinder
authors.initials: R
authors.lastname: Sudini
authors.forename: Michael A
authors.initials: MA
authors.lastname: McGuire
authors.forename: Dharmesh S
authors.initials: DS
authors.lastname: Bhanushali
authors.forename: Alireza S
authors.initials: AS
authors.lastname: Kord
mesh_terms: D004340:Drug Contamination; D007191:Indazoles; D011743:Pyrimidines / Q000032:analysis* / Q000737:chemistry / Q000302:isolation & purification; D013449:Sulfonamides / Q000032:analysis* / Q000737:chemistry / Q000302:isolation & purification; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib